Target Modulation by a Kinase Inhibitor Engineered to Induce a Tandem Blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: The Concept of Type III Combi-Targeting
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Target Modulation by a Kinase Inhibitor Engineered to Induce a Tandem Blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: The Concept of Type III Combi-Targeting
Authors
Keywords
Hydrolysis, Kinase inhibitors, Tyrosine kinases, Phosphorylation, Cancer treatment, Prototypes, Drug therapy, Apoptosis
Journal
PLoS One
Volume 10, Issue 2, Pages e0117215
Publisher
Public Library of Science (PLoS)
Online
2015-02-07
DOI
10.1371/journal.pone.0117215
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Advances in the development of hybrid anticancer drugs
- (2013) Sébastien Fortin et al. Expert Opinion on Drug Discovery
- Biological Effects of AL622, a Molecule Rationally Designed to Release an EGFR and a c-Src Kinase Inhibitor
- (2012) Anne-Laure Larroque-Lombard et al. Chemical Biology & Drug Design
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Species Difference of Esterase Expression and Hydrolase Activity in Plasma
- (2012) Fatma Goksin Bahar et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Chemical genetic discovery of targets and anti-targets for cancer polypharmacology
- (2012) Arvin C. Dar et al. NATURE
- Polypharmacology: drug discovery for the future
- (2012) A Srinivas Reddy et al. Expert Review of Clinical Pharmacology
- Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome Gefitinib-resistance in non-small cell lung cancer cell lines
- (2011) H Li et al. Advances in Medical Sciences
- Src: a potential target for the treatment of triple-negative breast cancer
- (2011) D. Tryfonopoulos et al. ANNALS OF ONCOLOGY
- Synthesis and Studies on Three-Compartment Flavone-Containing Combi-Molecules Designed to Target EGFR, DNA, and MEK
- (2011) Anne-Laure Larroque-Lombard et al. Chemical Biology & Drug Design
- Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents
- (2011) Carina Neto et al. NUCLEAR MEDICINE AND BIOLOGY
- The combi-targeting concept: Mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle
- (2010) Ranjita Banerjee et al. CELLULAR SIGNALLING
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis and Uptake of Fluorescence-Labeled Combi-molecules by P-Glycoprotein-Proficient and -Deficient Uterine Sarcoma Cells MES-SA and MES-SA/DX5
- (2010) Anne-Laure Larroque-Lombard et al. JOURNAL OF MEDICINAL CHEMISTRY
- Subcellular Distribution of a Fluorescence-Labeled Combi-Molecule Designed to Block Epidermal Growth Factor Receptor Tyrosine Kinase and Damage DNA with a Green Fluorescent Species
- (2010) Margarita I. Todorova et al. MOLECULAR CANCER THERAPEUTICS
- Src inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling
- (2009) Jyoti Nautiyal et al. CANCER LETTERS
- Rational Design of Multitargeted Tyrosine Kinase Inhibitors: A Novel Approach
- (2009) Sylvie Barchéchath et al. Chemical Biology & Drug Design
- Hybrid Compound Design To Overcome the Gatekeeper T338M Mutation in cSrc#
- (2009) Matthäus Getlik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Synthesis of Water Soluble Bis-triazenoquinazolines: An Unusual Predicted Mode of Binding to the Epidermal Growth Factor Receptor Tyrosine Kinase
- (2008) Anne-Laure Larroque et al. Chemical Biology & Drug Design
- Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma
- (2008) P. Koppikar et al. CLINICAL CANCER RESEARCH
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- Do molecularly targeted agents in oncology have reduced attrition rates?
- (2008) Ian Walker et al. NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search